France’s National Center for Scientific Research (CNRS) has selected 10 start-ups with innovative technologies to showcase at the Viva Technology conference in Paris, France from May 22-25, 2024. Among them is Vect-Horus, a biotechnology company based in Marseille, France.
Vect-Horus specializes in designing molecular vectors that aid in the targeted delivery of therapeutic molecules and imaging agents. The company was founded in 2005 as a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University). They focus on developing vectors for targeting and delivering therapeutic or imaging agents to organs and tumors.
Vect-Horus’ CEO, Jean-Manuel Pean, will be part of a roundtable discussion where he will provide an overview of the company and its pipeline. He will discuss the progress made with their unique breakthrough technology VECTrans®, which is a novel approach to drug targeting for the brain and other pathological tissues such as cancers. He will also discuss their early clinical trials of their theragnostic agent for glioblastoma and pancreatic cancer and provide updates on their partnerships with Novo Nordisk and Ionis Pharmaceuticals.
The detailed roundtable program will be announced closer to the event. With 38 employees predominantly in research and development, Vect-Horus continues to make strides in the biotechnology field. For more information about Vect-Horus, visit their website at www.vect-horus.com. For media inquiries or press releases, contact Vect-Horus at contact@vect-horus.com. For any other information, reach out to their Business Development and Alliance Manager, Emmanuelle Bettendorf or the media relations team at Cohesion Bureau.
